Empagliflozin Trims Liver Fat in Patients With T2D and NAFLD Empagliflozin Trims Liver Fat in Patients With T2D and NAFLD

Dr Kuchay discusses his findings from the E-LIFT study.Endocrine Society
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Related Links:

This study was conducted among 160 diabetic patients with NAFLD proven biopsy. Anthropometric assessments, laboratory test, liver histological features and follow-up of a Mediterranean diet were evaluated.ResultsDiabetic patients with liver fibrosis showed a greater number of positive metabolic criteria than diabetic patients without liver fibrosis. Patients with hepatic fibrosis have a lower score on the PREDIMED test (9.0 (2.4) vs. 6.2 (2.3);p 
Source: Endocrine - Category: Endocrinology Source Type: research
We present an up-to-date systematic review of the current literature regarding the safety in artificial and natural sweeteners use as a means of weight loss or diabetes control.Expert opinion: Natural sweeteners have not been associated directly with NAFLD, and on the contrary, some, such as stevia, and trehalose, may have a protective effect. Rare sugars and polyols can be used safely and have significant benefits that include anti-oxidant effect and optimal glycemic control. Artificial sweeteners, due to their effect on NAFLD development and insulin resistance, are not indicated in patients with obesity or diabetes. Furt...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Conclusion: Serum GGT level was a significant predictor of subsequent risk of diabetes mellitus, which increased by 4% for every 1 IU/L increase in GGT when GGT was less than 24 IU/L. PMID: 32215009 [PubMed]
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
We read with great interest the article by Byrne et  al. who summarized recent advances in the association between non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD), and reported that the prevalence rate of CKD in patients with NAFLD ranged from 20% to 55%.1 Given a high cardiovascular disease-specific mortality among NAFLD populations (4.79 per 1,000 person-years, 95% CI 3.43–6.70), NAFLD-related cardiovascular events have filtered into people's minds.2 By contrast, although CKD is another closely related extrahepatic disease, the burden of CKD, especially the incidence of CKD, has not ...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research
This article is a meta ‐analysis that evaluates the efficacy of sodium–glucose cotransporter 2 inhibitors on the treatment of non‐alcoholic fatty liver disease. The results show that sodium–glucose cotransporter 2 inhibitors can significantly decrease alanine aminotransferase and magnetic resonance imaging proto n density fat fraction, accompanied with the reduction of weight and visceral fat areas. We can conclude that sodium–glucose cotransporter 2 inhibitor is a new option to treat non‐alcoholic fatty liver disease in the future. AbstractAims/IntroductionNon ‐alcoholic fatty live...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Original Article Source Type: research
Publication date: Available online 23 March 2020Source: Canadian Journal of DiabetesAuthor(s): Nobuko Kitagawa, Yoshitaka Hashimoto, Masahide Hamaguchi, Takafumi Osaka, Takuya Fukuda, Masahiro Yamazaki, Michiaki Fukui
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
ConclusionUltrasonographically acquired HRI has a significant predictive impact on the detection of prediabetes and diabetes in patients with NAFLD.
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
CONCLUSION: The molecular mechanism of "CHLZT" in the treatment of NAFLD indicated the synergistic features of multi-component, multi-target, and multi-pathway of traditional Chinese medicine, which provided an important scientific basis for further elucidating the mechanism of "CHLZT" in the treatment of NAFLD. PMID: 32208163 [PubMed - as supplied by publisher]
Source: Computational Biology and Chemistry - Category: Bioinformatics Authors: Tags: Comput Biol Chem Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease nowadays. Changes in diet and lifestyle have led to a dramatic increase in the prevalence of NAFLD around t...
Source: BMC Gastroenterology - Category: Gastroenterology Authors: Tags: Research article Source Type: research
More News: Diabetes | Empagliflozin | Endocrinology | Health | Jardiance | Liver | Non-alcoholic Fatty Liver Diseases (NAFLD) | Study | Urology & Nephrology